| Nov 7 |
Arcutis Biotherapeutics Inc (ARQT) Q3 2024 Earnings Call Highlights: Robust Growth and ...
|
| Nov 6 |
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q3 Loss, Tops Revenue Estimates
|
| Nov 6 |
Arcutis Biotherapeutics GAAP EPS of -$0.33 beats by $0.09, revenue of $44.75M beats by $7.41M
|
| Nov 6 |
Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update
|
| Nov 6 |
High Growth Tech Stocks In The United States To Watch
|
| Nov 5 |
Arcutis Biotherapeutics Q3 2024 Earnings Preview
|
| Oct 25 |
Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
|
| Oct 24 |
Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting
|
| Oct 23 |
Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference
|
| Oct 22 |
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4
|
